Manages plasma uric acid levels. Sold as Elitek. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Rasburicase (sold as Elitek), first approved Jul 12, 2002, with 1 new use approved and 0 published complete response letters.
| Elitek | Part B | $10.7M | +1% | 1,523 |
| Elitek | Part D | $2.4M | +27% | 250 |
| A Study of IN026 in Participants With Refractory GoutRefractory Gout · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 | Recruiting | May 14, 2026 |
| Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed PatientsGout, Gouty Arthritis · Arthrosi Therapeutics | Phase 2 | Active, not recruiting | Aug 12, 2025 |
| Mature B-Cell Lymphoma And Leukemia Study IIIMature B-Cell Lymphoma · St. Jude Children's Research Hospital | Phase 2 / Phase 3 | Active, not recruiting | Jan 12, 2010 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 12, 2002 | ElitekBLA 103946 · New molecular entity | Sanofi Synthelabo | 10 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
